Cumberland Pharmaceuticals (CPIX) Cash from Operations Growth (5y) (2015 - 2026)
Analysis
Cumberland Pharmaceuticals (CPIX) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn |
| 10 | Cumberland Pharmaceuticals | 96.11 Mn | 92.24 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -28.02% |
| Mar 31, 2026 | -26.35% |
| Dec 31, 2025 | -67.65% |
| Sep 30, 2025 | -26.24% |
| Jun 30, 2025 | -21.42% |
| Mar 31, 2025 | 34.41% |
| Dec 31, 2024 | 17.32% |
| Sep 30, 2024 | -8.33% |
| Jun 30, 2024 | -19.24% |
| Mar 31, 2024 | -28.13% |
| Dec 31, 2023 | -22.51% |
| Sep 30, 2023 | 22.46% |
| Jun 30, 2023 | 45.82% |
| Mar 31, 2023 | -51.65% |
| Dec 31, 2022 | 58.22% |
| Sep 30, 2022 | 21.56% |
| Jun 30, 2022 | 23.91% |
| Mar 31, 2022 | -16.05% |
| Dec 31, 2021 | 19.04% |
| Sep 30, 2021 | -18.61% |